Bellicum Pharmaceuticals, Inc. - BLCM STOCK NEWS

Bellicum Pharmaceuticals (NASDAQ:BLCM) has initiated enrollment for the Phase 1/2 clinical trial of BPX-603, targeting HER2-expressing tumors. This represents an important milestone as the first patient has been enrolled, marking the second GoCAR-T program to enter clinical trials. The trial aims to assess the safety and efficacy of BPX-603 in patients with advanced solid tumors. The study will evaluate various tumor types including gastric, breast, and colorectal cancers. BPX-603 employs Bellicum’s innovative dual-switch technology to enhance immune response while ensuring safety.

Bellicum Pharmaceuticals (NASDAQ:BLCM) has announced a clinical hold on its Phase 1/2 trial of BPX-601, following a patient death deemed unrelated to the treatment. The FDA has placed this hold to review safety concerns. Despite this setback, Bellicum plans to continue with plans to initiate enrollment for its BPX-603 trial targeting HER2+ solid tumors by year-end. BPX-601, designed to treat pancreatic and prostate cancers, leverages a next-generation CAR-T technology for enhanced immune response.

Bellicum Pharmaceuticals reported a net loss of $0.9 million for Q3 2020, down from $32 million in Q3 2019. The company raised approximately $25 million through a stock offering to strengthen its balance sheet. Bellicum plans to initiate Phase 1/2 trials for BPX-601 in mCRPC and BPX-603 in HER2+ tumors by year-end. R&D expenses decreased to $8.1 million from $14.3 million YoY. Cash and equivalents stood at $54.6 million as of September 30, 2020, expected to fund operations into Q2 2022, signaling improved financial management.

Bellicum Pharmaceuticals (Nasdaq:BLCM) has completed an underwritten public offering, raising approximately $25 million. The offering included 1,040,000 shares of common stock, pre-funded warrants for 3,109,378 shares, and accompanying warrants for an additional 4,149,378 shares. Each common share was sold at $6.025, while pre-funded warrants were priced at $6.024. The exercise prices for the warrants are set at $0.001 and $6.50 per share, respectively. H.C. Wainwright & Co. managed the offering.

Bellicum Pharmaceuticals (Nasdaq:BLCM) has priced an underwritten offering of 4,149,378 shares of common stock and accompanying warrants, raising approximately $25 million. Each share is sold at a combined effective price of $6.025. The funds will support ongoing clinical trials for BPX-601 and BPX-603 and general corporate purposes. Closing is anticipated on November 3, 2020. The securities are offered under a shelf registration statement effective since July 30, 2019. This press release does not constitute an offer to sell securities.

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced interim data from its BPX-601 clinical trial for relapsed/refractory metastatic pancreatic cancer, showing evidence of CAR-T cell activation but no meaningful efficacy. The company plans to restructure, reducing staff by 79% to focus on GoCAR-T candidates BPX-601 and BPX-603, while pausing the BCMA GoCAR-NK program. It expects to incur $2.5 million in severance expenses and aims to manage annual cash utilization of $25 to $30 million. Bellicum is also set to pay down $27.4 million in debt by October 30, 2020.

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced participation in two virtual investor conferences. The first is the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 12:40 p.m. EDT, featuring an analyst moderated discussion. The second is the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:30 p.m. EDT, which will include a presentation. Live webcasts and archived versions of the events will be accessible on the company’s website.

Bellicum Pharmaceuticals (NASDAQ: BLCM) announced equity inducement grants of 13,680 stock options to three new employees on August 31, 2020. The grants were approved by the Compensation Committee as part of Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $5.95 per share, vesting over four years, with 25% vesting on the first anniversary and monthly thereafter, contingent upon continued employment. The options fall under the company's 2019 Equity Incentive Plan.

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced on July 31, 2020, the grant of 3,520 stock options to two new employees as part of their inducement to join the company. The exercise price for these options is set at $6.71 per share, and they will vest over four years, with a quarter vesting after one year and the remainder monthly thereafter. This action conforms with Nasdaq Listing Rule 5635(c)(4) and is part of the company’s 2019 Equity Incentive Plan. Bellicum specializes in developing controllable cellular immunotherapies for cancer treatment.